Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of CDTX is 222 and suggests 0% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
Buy
Sell